載入...
Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial
BACKGROUND: Certain disadvantages of the standard hematopoietic stem and progenitor cell (HSPC) mobilizing agent G-CSF fuel the quest for alternatives. We herein report results of a Phase I dose escalation trial comparing mobilization with a peptidic CXCR4 antagonist POL6326 (balixafortide) vs. G-CS...
Na minha lista:
| 發表在: | J Transl Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5209880/ https://ncbi.nlm.nih.gov/pubmed/28049490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-1107-2 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|